Contact information
matthew.wood@paediatrics.ox.ac.uk
01865 272419
01865 282840
Louise Gillane
mjaw-pa@paediatrics.ox.ac.uk
Research groups
Matthew Wood
Professor of Neuroscience
Matthew Wood graduated in Medicine from the University of Cape Town in 1987, working in clinical Neuroscience before gaining a doctorate in Physiological Sciences from the University of Oxford in 1993. He is currently University Lecturer, and Fellow and Tutor in Medicine and Physiology at Somerville College.
Matthew’s research is in field of gene therapy for degenerative disorders of the nervous system and muscle. The main focus is the investigation of novel therapeutic approaches utilising short nucleic acids to target messenger RNA. Targeting RNA has the potential to allow modification of the target transcript, reprogramming of endogenous genetic defects or the targeting of specific disease alleles, all the while maintaining endogenous regulation of the target gene. Current work is investigating the potential of single-stranded antisense oligonucleotides for the modification of mRNA splicing, for example in Duchenne muscular dystrophy. In addition, the potential of double-stranded RNA for gene silencing, known as RNA interference (RNAi), is being investigated for the silencing of target genes and mutant alleles both in muscle and in the nervous system. In particular, RNAi has great potential as a future therapeutic agent for currently untreatable neurodegenerative disorders such as Parkinson’s disease.
Key publications
-
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes.
Journal article
Alvarez-Erviti L. et al, (2011), Nat Biotechnol, 29, 341 - 345
Recent publications
-
Peptide-conjugated antimiRs improve myotonic dystrophy type 1 phenotypes by promoting endogenous MBNL1 expression.
Journal article
González-Martínez I. et al, (2023), Mol Ther Nucleic Acids, 34
-
An Induced Pluripotent Stem Cell-Derived Human Blood-Brain Barrier (BBB) Model to Test the Crossing by Adeno-Associated Virus (AAV) Vectors and Antisense Oligonucleotides.
Journal article
Selvakumaran J. et al, (2023), Biomedicines, 11
-
PRMT inhibitor promotes SMN2 exon 7 inclusion and synergizes with nusinersen to rescue SMA mice.
Journal article
Kordala AJ. et al, (2023), EMBO Mol Med
-
Modulation of Pro-Inflammatory IL-6 Trans-Signaling Axis by Splice Switching Oligonucleotides as a Therapeutic Modality in Inflammation.
Journal article
Gupta D. et al, (2023), Cells, 12
-
Therapeutic approaches for Duchenne muscular dystrophy.
Journal article
Roberts TC. et al, (2023), Nat Rev Drug Discov